デフォルト表紙
市場調査レポート
商品コード
1473238

細胞療法関連の提携とライセンス契約 (2016~2024年)

Cell Therapy Collaboration and Licensing Deals 2016-2024

出版日: | 発行: Current Partnering | ページ情報: 英文 500+ Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.74円
細胞療法関連の提携とライセンス契約 (2016~2024年)
出版日: 2024年05月01日
発行: Current Partnering
ページ情報: 英文 500+ Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、細胞療法に関連する昨今 (2016~2024年) の提携とライセンス契約の動向について分析し、全体的な取引形成件数の推移や、財務面 (支払条件) の傾向、主要企業 (全25社) による取引形成の動き、契約条件の傾向、技術別の傾向などを調査すると共に、近年の主要な提携取引の詳細情報を取りまとめてお届けいたします。

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 細胞療法関連の取引形成の傾向

  • イントロダクション
  • 細胞療法関連の取引の長期的動向
  • 細胞療法関連で最も活発な取引業者
  • 細胞療法関連の取引:取引の種類別
  • 細胞療法関連の取引:治療分野別
  • 細胞療法関連の取引:業界別
  • 細胞療法関連の取引:取引条件
    • 細胞療法関連の取引:取引総額
    • 細胞療法関連の取引:前払い金
    • 細胞療法関連の取引:マイルストーン払い
    • 細胞療法関連の取引:ロイヤルティ率

第3章 細胞療法関連の主な取引

  • イントロダクション
  • 細胞療法関連の主要な取引:取引金額ベース

第4章 細胞療法関連で最も活発な取引企業

  • イントロダクション
  • 細胞療法関連の取引で最も活発な企業
  • 細胞療法関連で最も活発な取引企業:プロファイル

第5章 細胞療法関連の取引形成の一覧

  • イントロダクション
  • 細胞療法関連の取引締結の一覧

第6章 細胞療法関連の取引:技術の種類別

  • 取引一覧
  • 取引一覧:細胞療法関連、企業別 (ABC順)
  • 取引一覧:細胞療法関連、取引の種類別
  • 取引一覧:細胞療法関連、治療分野別
  • 取引の種類の定義
  • Biopharma Research Ltdについて
  • 現在の提携
  • 現在の契約
  • Current Partnering刊行の最近のレポートタイトル
目次
Product Code: CP21161

Cell Therapy Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cell therapy deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of cell therapy deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter cell therapy deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 910 cell therapy deals announced since 2016 including financial terms where available including links to online deal records of actual cell therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of cell therapy dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in cell therapy dealmaking since 2016.

Chapter 3 provides an overview of the leading cell therapy deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in cell therapy dealmaking with a brief summary followed by a comprehensive listing of cell therapy deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of cell therapy deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of cell therapy partnering deals signed and announced since Jan 2016. The chapter is organized by specific cell therapy technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in cell therapy deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Cell Therapy Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse cell therapy collaboration and licensing deals
  • Benchmark analysis - identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, deal type and therapy area
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Report scope

  • Cell Therapy Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cell therapy trends and structure of deals entered into by leading biopharma companies worldwide.

Cell Therapy Collaboration and Licensing Deals includes:

  • Trends in cell therapy dealmaking in the biopharma industry
  • Directory of cell therapy deal records covering pharmaceutical and biotechnology
  • The leading cell therapy deals by value
  • Most active cell therapy licensing dealmakers
  • Cell Therapy Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cell therapy dealmaking

  • 2.1. Introduction
  • 2.2. Cell therapy deals over the years
  • 2.3. Most active cell therapy dealmakers
  • 2.4. Cell therapy deals by deal type
  • 2.5. Cell therapy deals by therapy area
  • 2.6. Cell therapy deals by industry sector
  • 2.7. Deal terms for cell therapy deals
    • 2.7.1 Cell therapy deals headline values
    • 2.7.2 Cell therapy deal upfront payments
    • 2.7.3 Cell therapy deal milestone payments
    • 2.7.4 Cell therapy royalty rates

Chapter 3 - Leading cell therapy deals

  • 3.1. Introduction
  • 3.2. Top cell therapy deals by value

Chapter 4 - Most active cell therapy dealmakers

  • 4.1. Introduction
  • 4.2. Most active cell therapy dealmakers
  • 4.3. Most active cell therapy deals company profiles

Chapter 5 - Cell therapy contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Cell therapy contracts dealmaking directory

Chapter 6 - Cell therapy dealmaking by technology type

  • Deal directory
  • Deal directory - Cell therapy deals by company A-Z
  • Deal directory - Cell therapy deals by deal type
  • Deal directory - Cell therapy deals by therapy area
  • Deal type definitions
  • About Biopharma Research Ltd
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Cell therapy deals since 2016
  • Figure 2: Active cell therapy dealmaking activity - 2016 - 2024
  • Figure 3: Cell therapy deals by deal type since 2016
  • Figure 4: Cell therapy deals by therapy area since 2016
  • Figure 5: Cell therapy deals by industry sector since 2016
  • Figure 6: Cell therapy deals with a headline value
  • Figure 7: Cell therapy deals with an upfront value
  • Figure 8: Cell therapy deals with a milestone value
  • Figure 9: Cell therapy deals with a royalty rate value
  • Figure 10: Top cell therapy deals by value since 2016
  • Figure 11: Most active cell therapy dealmakers 2016 - 2024
  • Figure 12: Cell therapy deals by technology type since 2016